Sentiment-Signal
16,1
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
BeOne Medicines, formerly known as BeiGene, is a global oncology company focused on discovering, developing, and commercializing innovative cancer therapies. Founded in 2010 and headquartered in Cambridge, Massachusetts—with operations spanning over 45 countries across six continents—the company rebranded as BeOne in late 2024 and redomiciled to Basel, Switzerland in 2025. BeOne has established itself as a leader in immuno-oncology and targeted therapies, with key assets including Tevimbra (tislelizumab), a PD-1 monoclonal antibody approved for multiple cancer indications globally, and Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor that surpassed $1.3 billion in annual sales and is approved in major markets such as the U.S., Europe, and China. The company’s strategy combines internal R&D with the development of assets sourced from external partnerships, driving a robust pipeline across hematologic malignancies and solid tumors.
Unternehmen & Branche
| Name | BeOne Medicines Ltd. |
|---|---|
| Ticker | ONC |
| CIK | 0001651308 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Pharmaceuticals |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | ADR |
| Marktkapitalisierung | 31,93 Mrd. USD |
| Beta | 0,54 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 5,343,033,000 | 286,933,000 | 0.19 | 8,188,573,000 | 4,361,194,000 |
| 2025-09-30 | 10-Q | 1,412,284,000 | 124,841,000 | 0.08 | 7,632,586,000 | 4,129,326,000 |
| 2025-06-30 | 10-Q | 1,315,300,000 | 94,320,000 | 0.06 | 6,298,394,000 | 3,770,475,000 |
| 2025-03-31 | 10-Q | 1,117,279,000 | 1,270,000 | 0.00 | 5,841,526,000 | 3,499,513,000 |
| 2024-12-31 | 10-K | 3,810,241,000 | -644,786,000 | -0.47 | 5,920,910,000 | 3,332,222,000 |
| 2024-09-30 | 10-Q | 1,001,599,000 | -121,350,000 | -0.09 | 5,830,860,000 | 3,436,073,000 |
| 2024-06-30 | 10-Q | 929,166,000 | -120,405,000 | -0.09 | 5,712,179,000 | 3,366,255,000 |
| 2024-03-31 | 10-Q | 751,652,000 | -251,150,000 | -0.19 | 5,667,681,000 | 3,360,361,000 |
| 2023-12-31 | 10-K | 2,458,779,000 | -881,708,000 | -0.65 | 5,805,275,000 | 3,537,327,000 |
| 2023-09-30 | 10-Q | 781,308,000 | 215,413,000 | 0.15 | 5,524,879,000 | 3,763,234,000 |
| 2023-06-30 | 10-Q | 595,261,000 | -381,137,000 | -0.28 | 5,728,736,000 | 3,798,559,000 |
| 2023-03-31 | 10-Q | 447,801,000 | -348,431,000 | -0.26 | 5,956,775,000 | 4,157,306,000 |
| 2022-12-31 | 10-K | 1,415,921,000 | -2,003,815,000 | -1.49 | 6,379,290,000 | 4,383,355,000 |
| 2022-09-30 | 10-Q | 387,628,000 | -557,556,000 | -0.41 | 6,726,013,000 | 4,655,171,000 |
| 2022-06-30 | 10-Q | 341,572,000 | -565,726,000 | -0.42 | 7,378,207,000 | 5,196,919,000 |
| 2022-03-31 | 10-Q | 306,626,000 | -435,198,000 | -0.33 | 8,021,388,000 | 5,774,152,000 |
| 2021-12-31 | 10-K | 1,176,283,000 | -1,457,816,000 | -1.21 | 8,535,525,000 | 6,132,563,000 |
| 2021-09-30 | 10-Q | 206,440,000 | -438,114,000 | -0.36 | 5,286,334,000 | 3,357,073,000 |
| 2021-06-30 | 10-Q | 149,992,000 | -480,341,000 | -0.40 | 5,524,116,000 | 3,606,775,000 |
| 2021-03-31 | 10-Q | 605,872,000 | 66,495,000 | 0.05 | 5,821,004,000 | 4,003,587,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-08 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -332 | 311.59 | -103,447.88 | -12,6% | |
| 2026-02-04 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -996 | 350.00 | -348,600.00 | -42,4% | |
| 2026-02-04 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -664 | 348.79 | -231,596.56 | -28,2% | |
| 2026-01-07 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -664 | 331.76 | -220,288.64 | -26,8% | |
| 2025-12-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -1,973 | 304.36 | -600,507.41 | -73,0% | |
| 2025-12-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -1,877 | 300.80 | -564,596.53 | -68,7% | |
| 2025-12-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -1,633 | 303.13 | -495,012.60 | -60,2% | |
| 2025-12-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -1,512 | 302.31 | -457,096.80 | -55,6% | |
| 2025-12-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -1,255 | 304.13 | -381,684.66 | -46,4% | |
| 2025-12-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -40 | 305.24 | -12,209.60 | -1,5% | |
| 2025-12-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -600 | 300.98 | -180,586.26 | -22,0% | |
| 2025-12-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -7,470 | 302.74 | -2,261,491.70 | -275,0% | |
| 2025-12-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -5,442 | 303.72 | -1,652,854.58 | -201,0% | |
| 2025-12-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -2,567 | 301.79 | -774,699.29 | -94,2% | |
| 2025-12-15 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -4,949 | 306.39 | -1,516,335.00 | -184,4% | |
| 2025-12-15 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -16,318 | 310.48 | -5,066,489.33 | -616,2% | |
| 2025-12-15 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -14,163 | 308.41 | -4,368,017.91 | -531,2% | |
| 2025-12-15 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -10,650 | 309.37 | -3,294,797.96 | -400,7% | |
| 2025-12-15 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -6,389 | 302.29 | -1,931,330.81 | -234,9% | |
| 2025-12-15 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -5,829 | 304.37 | -1,774,160.49 | -215,8% | |
| 2025-12-15 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -5,118 | 307.38 | -1,573,167.77 | -191,3% | |
| 2025-12-15 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -3,940 | 305.55 | -1,203,866.61 | -146,4% | |
| 2025-12-15 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -2,344 | 311.33 | -729,749.08 | -88,8% | |
| 2025-12-15 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -1,896 | 303.60 | -575,628.82 | -70,0% | |
| 2025-12-15 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -1,791 | 301.58 | -540,126.74 | -65,7% | |
| 2025-12-15 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -1,194 | 314.92 | -376,009.35 | -45,7% | |
| 2025-12-15 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -929 | 313.52 | -291,256.09 | -35,4% | |
| 2025-12-15 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -121 | 311.93 | -37,743.45 | -4,6% | |
| 2025-12-11 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -332 | 325.00 | -107,900.00 | -13,1% | |
| 2025-12-10 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -332 | 318.28 | -105,668.96 | -12,9% | |
| 2025-11-26 | Sanders Corazon (Corsee) D. | Director | Open Market Sale | -1,823 | 340.20 | -620,185.33 | -75,4% | |
| 2025-11-26 | Sanders Corazon (Corsee) D. | Director | Open Market Sale | -804 | 342.47 | -275,349.10 | -33,5% | |
| 2025-11-17 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -3,155 | 380.23 | -1,199,617.45 | -145,9% | |
| 2025-11-17 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -826 | 381.19 | -314,862.20 | -38,3% | |
| 2025-11-17 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -10 | 382.32 | -3,823.20 | -0,5% | |
| 2025-11-13 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -4,240 | 380.33 | -1,612,582.66 | -196,1% | |
| 2025-11-13 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -1,769 | 381.05 | -674,076.92 | -82,0% | |
| 2025-11-12 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -100 | 357.43 | -35,743.18 | -4,3% | |
| 2025-11-12 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -120 | 355.00 | -42,600.00 | -5,2% | |
| 2025-11-12 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -664 | 348.75 | -231,570.00 | -28,2% | |
| 2025-11-12 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -332 | 350.00 | -116,200.00 | -14,1% | |
| 2025-11-12 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -4,846 | 360.10 | -1,745,024.25 | -212,2% | |
| 2025-11-12 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -3,240 | 351.41 | -1,138,569.05 | -138,5% | |
| 2025-11-12 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -789 | 352.78 | -278,341.29 | -33,9% | |
| 2025-11-12 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -500 | 350.44 | -175,220.50 | -21,3% | |
| 2025-11-12 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -251 | 354.20 | -88,903.30 | -10,8% | |
| 2025-11-12 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -154 | 362.07 | -55,759.07 | -6,8% | |
| 2025-10-08 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -4,162 | 351.12 | -1,461,374.76 | -177,7% | |
| 2025-10-08 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -664 | 347.82 | -230,952.48 | -28,1% | |
| 2025-10-08 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -4,733 | 350.22 | -1,657,580.37 | -201,6% | |
| 2025-10-08 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -1,112 | 350.00 | -389,200.00 | -47,3% | |
| 2025-09-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -4,066 | 324.12 | -1,317,862.16 | -160,3% | |
| 2025-09-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -400 | 327.78 | -131,112.00 | -15,9% | |
| 2025-09-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -12,446 | 326.14 | -4,059,091.15 | -493,7% | |
| 2025-09-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -6,883 | 325.06 | -2,237,401.75 | -272,1% | |
| 2025-09-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -4,008 | 326.90 | -1,310,226.82 | -159,3% | |
| 2025-09-10 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -3,318 | 325.73 | -1,080,760.20 | -131,4% | |
| 2025-09-10 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -300 | 326.80 | -98,040.00 | -11,9% | |
| 2025-09-10 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -500 | 327.93 | -163,965.00 | -19,9% | |
| 2025-09-10 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -1,112 | 325.00 | -361,400.00 | -44,0% | |
| 2025-09-10 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -4,776 | 325.19 | -1,553,123.68 | -188,9% | |
| 2025-09-09 | Wang Lai | Officer, Global Head of R&D | Open Market Sale | -5,000 | 350.06 | -1,750,311.50 | -212,9% | |
| 2025-09-05 | Sanders Corazon (Corsee) D. | Director | Open Market Sale | -2,665 | 337.00 | -898,105.00 | -109,2% | |
| 2025-08-01 | Rosenberg Aaron | Officer, Chief Financial Officer | Open Market Sale | -1,190 | 290.47 | -345,659.30 | -42,0% | |
| 2025-07-30 | Wang Lai | Officer, Global Head of R&D | Open Market Sale | -259 | 305.00 | -78,995.00 | -9,6% | |
| 2025-07-30 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -920 | 304.60 | -280,232.74 | -34,1% | |
| 2025-07-29 | Wang Lai | Officer, Global Head of R&D | Open Market Sale | -292 | 302.92 | -88,454.07 | -10,8% | |
| 2025-07-29 | Wang Lai | Officer, Global Head of R&D | Open Market Sale | -2,949 | 302.00 | -890,595.94 | -108,3% | |
| 2025-07-29 | Wang Lai | Officer, Global Head of R&D | Open Market Sale | -800 | 304.16 | -243,330.40 | -29,6% | |
| 2025-07-18 | Wang Lai | Officer, Global Head of R&D | Open Market Sale | -700 | 300.00 | -210,000.00 | -25,5% | |
| 2025-07-09 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -6,703 | 252.23 | -1,690,682.27 | -205,6% | |
| 2025-07-09 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -10,254 | 254.10 | -2,605,577.29 | -316,9% | |
| 2025-07-09 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -9,292 | 253.18 | -2,352,574.58 | -286,1% | |
| 2025-07-09 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -1,553 | 254.83 | -395,756.74 | -48,1% | |
| 2025-06-24 | Wang Xiaodong | Director | Open Market Sale | -1,100 | 265.35 | -291,887.75 | -35,5% | |
| 2025-06-24 | Wang Xiaodong | Director | Open Market Sale | -300 | 263.50 | -79,050.00 | -9,6% | |
| 2025-06-24 | Wang Xiaodong | Director | Open Market Sale | -100 | 267.81 | -26,781.00 | -3,3% | |
| 2025-06-24 | Wang Xiaodong | Director | Open Market Sale | -507 | 266.57 | -135,148.61 | -16,4% | |
| 2025-06-23 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -1,363 | 260.00 | -354,380.00 | -43,1% | |
| 2025-06-23 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -3,074 | 261.57 | -804,069.87 | -97,8% | |
| 2025-06-23 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -100 | 262.90 | -26,290.00 | -3,2% | |
| 2025-06-23 | Wang Lai | Officer, Global Head of R&D | Open Market Sale | -1,028 | 260.00 | -267,280.00 | -32,5% | |
| 2025-06-17 | Wang Lai | Officer, Global Head of R&D | Open Market Sale | -470 | 251.37 | -118,141.55 | -14,4% | |
| 2025-06-17 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -1,460 | 256.49 | -374,473.21 | -45,5% | |
| 2025-06-17 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -630 | 250.87 | -158,047.22 | -19,2% | |
| 2025-06-16 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -422 | 266.50 | -112,463.00 | -13,7% | |
| 2025-06-16 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -1,443 | 265.47 | -383,072.49 | -46,6% | |
| 2025-06-16 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -100 | 266.22 | -26,622.00 | -3,2% | |
| 2025-06-16 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -3,680 | 266.05 | -979,046.34 | -119,1% | |
| 2025-06-16 | Wang Lai | Officer, Global Head of R&D | Open Market Sale | -1,177 | 266.40 | -313,557.51 | -38,1% | |
| 2025-06-11 | Ball Titus B. | Officer, Principal Accounting Officer | Open Market Sale | -134 | 258.36 | -34,620.05 | -4,2% | |
| 2025-06-10 | Wang Xiaodong | Director | Open Market Sale | -16,094 | 263.17 | -4,235,501.43 | -515,1% | |
| 2025-06-10 | Wang Xiaodong | Director | Open Market Sale | -15,878 | 262.20 | -4,163,262.41 | -506,3% | |
| 2025-06-10 | Wang Xiaodong | Director | Open Market Sale | -6,787 | 264.08 | -1,792,313.67 | -218,0% | |
| 2025-06-10 | Wang Xiaodong | Director | Open Market Sale | -2,901 | 261.20 | -757,753.09 | -92,2% | |
| 2025-06-10 | Wang Xiaodong | Director | Open Market Sale | -100 | 264.85 | -26,485.00 | -3,2% | |
| 2025-06-06 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -927 | 254.97 | -236,358.21 | -28,7% | |
| 2025-06-06 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -1,400 | 251.88 | -352,626.40 | -42,9% | |
| 2025-06-06 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -1,400 | 250.84 | -351,176.70 | -42,7% | |
| 2025-06-06 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -1,000 | 253.49 | -253,489.70 | -30,8% | |
| 2025-06-06 | Wang Lai | Officer, Global Head of R&D | Open Market Sale | -300 | 253.19 | -75,956.01 | -9,2% | |
| 2025-06-06 | Wang Lai | Officer, Global Head of R&D | Open Market Sale | -202 | 251.89 | -50,882.31 | -6,2% | |
| 2025-06-06 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -470 | 255.78 | -120,217.21 | -14,6% | |
| 2025-06-06 | Lee Chan Henry | Officer, SVP, General Counsel | Open Market Sale | -230 | 256.79 | -59,062.67 | -7,2% | |
| 2025-06-06 | OYLER JOHN | Director, Officer, Chief Executive Officer | Open Market Sale | -400 | 255.74 | -102,295.04 | -12,4% | |
| 2025-06-06 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -500 | 251.85 | -125,926.00 | -15,3% | |
| 2025-06-06 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -400 | 255.31 | -102,122.00 | -12,4% | |
| 2025-06-06 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -400 | 253.50 | -101,399.00 | -12,3% | |
| 2025-06-06 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -400 | 250.74 | -100,294.00 | -12,2% | |
| 2025-06-06 | Wu Xiaobin | Officer, President and COO | Open Market Sale | -234 | 255.77 | -59,850.02 | -7,3% | |
| 2025-06-06 | Wang Lai | Officer, Global Head of R&D | Open Market Sale | -600 | 250.71 | -150,424.98 | -18,3% | |
| 2025-06-06 | Wang Lai | Officer, Global Head of R&D | Open Market Sale | -300 | 255.30 | -76,590.00 | -9,3% | |
| 2025-05-13 | Wang Xiaodong | Director | Open Market Sale | -10,104 | 224.32 | -2,266,542.42 | -275,7% | |
| 2025-05-13 | Wang Xiaodong | Director | Open Market Sale | -21,235 | 223.41 | -4,744,092.24 | -577,0% | |
| 2025-05-13 | Wang Xiaodong | Director | Open Market Sale | -10,221 | 222.83 | -2,277,501.48 | -277,0% | |
| 2025-05-13 | Wang Xiaodong | Director | Open Market Sale | -200 | 225.68 | -45,136.00 | -5,5% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.